Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer

Current Cancer Drug Targets

Volumn 13, Issue 2, 2013, Pages 175-187

  Zhang, Xiaobei ^a,b   Li, Xi ru ^c   Zhang, Jin ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; mTOR inhibitors; PI3K inhibitors; PI3K AKT mTOR pathway

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 [4 [1 (1, 4 DIOXASPIRO [4.5] DEC 8 YL) 4 (8 OXA 3 AZABICYCLO [3.2.1] OCT 3 YL) 1H PYRAZOLO [3, 4 D] PYRIMIDIN 6 YL] PHENYL] 3 METHYLUREA; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4, 6 DIMORPHOLINO 1, 3, 5 TRIAZINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AROMATASE INHIBITOR; BEVACIZUMAB; BGT 226; BUPARLISIB; DOCETAXEL; EVEROLIMUS; GEMCITABINE; GSK 1059615; IDELALISIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 174; XL 765;

ADJUVANT THERAPY; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; ENDOMETRIUM CANCER; GENE MUTATION; HUMAN; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 84876863294     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313020007     Document Type: Review

References (95)

1. Hynes, N. E.; Boulay, A. The mTOR pathway in breast cancer. J. Mammary Gland Biol. Neoplasia. 2006, 11 (1), 53-61.
2. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 18, 27 (41), 5511-5526.
3. Ghayad, S. E.; Cohen, P. A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat. Anticancer Drug Discov. 2010, 5 (1), 29-57.
4. Chen, J. Z. Targeted therapy of obesity-associated colon cancer. Transl. Gastrointest Cancer 2012, 1, 44-57.
5. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5 (8), 671-688.
6. Myers, M. P.; Pass, I.; Batty, I. H.; Van der Kaay, J.; Stolarov, J. P.; Hemmings, B. A.; Wigler, M. H.; Downes, C. P.; Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA 1998, 95 (23), 13513-13518.
7. López-Knowles, E.; O'Toole, S. A.; McNeil, C. M.; Millar, E. K.; Qiu, M. R.; Crea, P.; Daly, R. J.; Musgrove, E. A.; Sutherland, R. L. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer 2010, 126 (5), 1121-1131.
8. Arnedos, M.; Weigelt, B.; Reis-Filho, J.S. Anti-HER2 therapies: When more is more. Transl. Cancer Res. 2012, 1 (1), 49-54.
9. Inoki K.; Zhu T.; Guan K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115 (5), 577-590.
10. Bertino, G. Hepatocellular carcinoma: present and future. Chin. Clin. Oncol. 2012, 1, 14.
11. Pene, F.; Claessens, Y. E.; Muller, O.; Viguié, F.; Mayeux, P.; Dreyfus, F.; Lacombe, C.; Bouscary, D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21 (43), 6587-6597.
12. Wang, X.; Proud, C. G. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006, 21, 362-369.
13. Hill, M.M.; Hemmings, B.A. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol. Ther. 2002, 93 (2-3), 243-251.
14. Nozawa, H.; Watanabe, T.; Nagawa, H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 2007, 251 (1), 105-13.
15. Zhou, X.; Tan, M.; Stone Hawthorne, V.; Klos, K. S.; Lan, K. H.; Yang, Y.; Yang, W.; Smith, T. L.; Shi, D.; Yu, D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res. 2004, 10 (20), 6779-6788.
16. Landriscina, M.; Esposito, F. Insulin-resistant conditions: A favorable milieu for aggressive drug-resistant malignancies. J. Gastrointest Oncol. 2011, 2 (1), 11-12.
17. Xu, G.; Zhang, W.; Bertram, P.; Zheng, X.F.; McLeod, H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. 2004, 24 (4), 893-900.
18. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627-644
19. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J. F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets. 2008, 8 (3), 187-98.
20. Bartholomeusz, C.; Gonzalez-Angulo, A. M. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16 (1), 121-130.
21. Saal, L. H.; Johansson, P.; Holm, K.; Gruvberger-Saal, S. K.; She, Q. B.; Maurer, M.; Koujak, S.; Ferrando, A. A.; Malmström, P.; Memeo, L.; Isola, J.; Bendahl, P. O.; Rosen, N.; Hibshoosh, H.; Ringnér, M.; Borg, A.; Parsons, R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 2007, 104 (18), 7564-7569.
22. Gonzalez-Angulo, A. M.; Ferrer-Lozano, J.; Stemke-Hale, K.; Sahin, A.; Liu, S.; Barrera, J. A.; Burgues, O.; Lluch, A. M.; Chen, H.; Hortobagyi, G. N.; Mills, G. B.; Meric-Bernstam, F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol. Cancer Ther. 2011, 10 (6), 1093-1101.
23. Perren, A.; Weng, L. P.; Boag, A. H.; Ziebold, U.; Thakore, K.; Dahia, P.L.; Komminoth, P.; Lees J. A.; Mulligan, L. M.; Mutter, G. L.; Eng, C.; Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155 (4), 1253-1260.
24. Bose, S.; Wang, S. I.; Terry, M. B.; Hibshoosh, H.; Parsons, R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998, 17 (1), 123-127.
25. Bose, S.; Crane, A.; Hibshoosh, H.; Mansukhani, M.; Sandweis, L.; Parsons, R.; Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 2002, 33 (4), 405-409.
26. Janku, F.; Wheler, J. J.; Westin, N.; Moulder, S. L.; Naing, A.; Tsimberidou, A. M.; Fu, S.; Falchook, G. S.; Hong, D. S.; Garrido-Laguna, I.; Luthra, R.; Lee, J. J.; Lu, K. H.; Kurzrock, R. PI3K/ AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 2012, 30 (8), 777-782.
27. Renehan, A. G.; Dive, C. Obesity, insulin and chemoresistance in colon cancer. J. Gastrointest. Oncol. 2011, 2 (1), 8-10.
28. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 2005, 102 (3), 802-807.
29. Baselga, J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 12-19.
30. Saal, L. H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J. S.; Malmström, P. O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65 (7), 2554-2559.
31. Stemke-Hale, K.; Gonzalez-Angulo, A. M.; Lluch, A.; Neve, R. M.; Kuo, W. L.; Davies, M.; Carey, M.; Hu, Z.; Guan, Y.; Sahin, A.; Symmans, W. F.; Pusztai, L.; Nolden, L. K.; Horlings, H.; Berns, K.; Hung, M. C.; van, de, Vijver, M. J.; Valero, V.; Gray, J. W.; Bernards, R.; Mills, G. B.; Hennessy, B. T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68 (15), 6084-6091.
32. Cheskis, B. J.; Greger, J.; Cooch, N.; McNally, C.; Mclarney, S.; Lam, H. S.; Rutledge, S.; Mekonnen, B.; Hauze, D.; Nagpal, S.; Freedman, L. P. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 2008, 73 (9-10), 901-905.
33. Kalinsky, K.; Jacks, L. M.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U. K.; Hedvat, C.V.; Traina, T. A.; Solit, D.; Gerald, W.; Moynahan, M. E. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 2009, 15 (16), 5049-5059.
34. Li, S. Y.; Rong, M.; Grieu, F.; Iacopetta, B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. 2006, 96 (1), 91-95.
35. Aleskandarany, M. A.; Rakha, E. A.; Ahmed, M. A.; Powe, D. G.; Paish, E. C.; Macmillan, R. D.; Ellis, I. O.; Green, A. R. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res. Treat. 2010, 122 (1), 45-53.
36. Park, B. H.; Davidson, N. E. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell 2007, 12 (4), 297-299.
37. Berns, K.; Horlings, H. M.; Hennessy, B. T.; Madiredjo, M.; Hijmans, E. M.; Beelen, K.; Linn, S. C.; Gonzalez-Angulo, A. M.; Stemke-Hale, K.; Hauptmann, M.; Beijersbergen, R. L.; Mills, G. B.; van de, Vijver, M. J.; Bernards, R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12 (4), 395-402.
38. Holbro, T.; Beerli, R. R.; Maurer, F.; Koziczak, M.; Barbas, C. F. 3rd.; Hynes, N. E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100 (15), 8933-8938.
39. Bange, J.; Prechtl, D.; Cheburkin, Y.; Specht, K.; Harbeck, N.; Schmitt, M.; Knyazeva, T.; Müller, S.; Gärtner, S.; Sures, I.; Wang, H.; Imyanitov, E.; Häring, H. U.; Knayzev, P.; Iacobelli, S.; Höfler, H.; Ullrich, A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002, 62 (3), 840-847.
40. Koziczak, M.; Holbro, T.; Hynes, N. E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004, 23 (20), 3501-3508.
41. Basso, A. D.; Mirza, A.; Liu, G.; Long, B. J.; Bishop, W. R.; Kirschmeier, P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 2005, 280 (35), 31101-31108.
42. Urano, J.; Sato, T.; Matsuo, T.; Otsubo, Y.; Yamamoto, M.; Tamanoi, F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl. Acad. Sci. USA 2007, 104 (9), 3514-3519.
43. Jiang, W. G.; Sampson, J.; Martin, T. A.; Lee-Jones, L.; Watkins, G.; Douglas-Jones, A.; Mokbel, K.; Mansel, R.E. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur. J. Cancer 2005, 41 (11), 1628-1636.
44. Yang, T. L.; Su, Y. R.; Huang, C. S.; Yu, J. C.; Lo, Y. L.; Wu, P. E.; Shen, C. Y. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosomes Cancer 2004, 41 (3), 250-256.
45. Fenton, H.; Carlile, B.; Montgomery, E. A.; Carraway, H.; Herman, J.; Sahin, F.; Su, G. H.; Argani, P. LKB1 protein expression in human breast cancer. Appl. Immunohistochem. Mol. Morphol. 2006, 14 (2), 146-153.
46. Wu, G. J.; Sinclair, C. S.; Paape, J.; Ingle, J. N.; Roche, P. C.; James, C. D.; Couch, F. J. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res. 2000, 60 (19), 5371-5375.
47. Bärlund, M.; Forozan, F.; Kononen, J.; Bubendorf, L.; Chen, Y.; Bittner, M. L.; Torhorst, J.; Haas, P.; Bucher, C.; Sauter, G.; Kallioniemi, O. P.; Kallioniemi, A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 2000, 92 (15), 1252-1259.
48. Li, B. D.; Gruner, J. S.; Abreo, F.; Johnson, L. W.; Yu, H.; Nawas, S.; McDonald, J. C.; DeBenedetti, A. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann. Surg. 2002, 235 (5), 732-738. discussion 738-739.
49. McClusky, D. R.; Chu, Q.; Yu, H.; Debenedetti, A.; Johnson, L. W.; Meschonat, C.; Turnage, R.; McDonald, J. C.; Abreo, F.; Li, B. D. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann. Surg. 2005, 242 (4), 584-590. discussion 590-592.
50. Zhou, S.; Wang, G. P.; Liu, C.; Zhou, M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 2006, 6, 231.
51. Wolfort, R.; de Benedetti, A.; Nuthalapaty, S.; Yu, H.; Chu, Q. D.; Li, B. D. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006, 140 (2), 161-169.
52. Graff, J. R.; Zimmer, S. G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastasis 2003, 20 (3), 265-273.
53. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta. 2008, 1784 (1), 159-185.
54. Workman, P.; Clarke, P. A.; Raynaud, F. I.; van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70 (6), 2146-2157.
55. Ng, S. S.; Tsao, M. S.; Nicklee, T.; Hedley, D. W. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 2001, 7 (10), 3269-3275.
56. Hu, L.; Hofmann, J.; Lu, Y.; Mills, G. B.; Jaffe, R. B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62 (4), 1087-1092.
57. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125 (4), 733-747.
58. Hernandez-Aya, L. F.; Gonzalez-Angulo, A. M. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011, 16 (4), 404-414.
59. Dan, S.; Okamura, M.; Mukai, Y.; Yoshimi, H.; Inoue, Y.; Hanyu, A.; Sakaue-Sawano, A.; Imamura, T.; Miyawaki, A.; Yamori, T. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. Eur. J. Cancer 2012, 48 (6); 936-943.
60. Chakrabarty, A.; Sánchez, V.; Kuba, M. G.; Rinehart, C.; Arteaga C. L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA 2012, 109 (8), 2718-2723.
61. Carvalho, S.; Schmitt, F. Potential role of PI3K inhibitors in the treatment of breast cancer. Future Oncol. 2010, 1251-1263.
62. Wu, P.; Su, Y.; Liu, X.; Zhang, L.; Ye, Y.; Xu, J.; Weng, S.; Li, Y.; Liu, T.; Huang, S.; Yang, B.; He, Q.; Hu, Y. Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl) quinoxalines as PI3Kα inhibitors. Eur. J. Med. Chem. 2011, 46 (11), 5540-5548.
63. Castillo, J. J.; Furman, M.; Winer, E. S. CAL-101:a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 2012, 21 (1), 15-22.
64. Creighton, C. J.; Fu, X.; Hennessy, B. T.; Casa, A. J.; Zhang, Y.; Gonzalez-Angulo, A. M.; Lluch, A.; Gray, J. W.; Brown, P. H.; Hilsenbeck, S. G.; Osborne, C. K.; Mills, G. B.; Lee, A. V.; Schiff, R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010, 12 (3), R40.
65. Xu, Y.; Sun, Q. Headway in resistance to endocrine therapy in breast cancer. J. Thorac. Dis. 2010, 2 (3), 171-177.
66. Markman, B.; Atzori, F.; Pérez-García, J.; Tabernero, J.; Baselga, J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol. 2010, 21 (4), 683-691
67. Bourguignon, L. Y.; Xia, W.; Wong, G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem. 2009, 284 (5), 2657-2671.
68. Sos, M. L.; Fischer, S.; Ullrich, R.; Peifer, M.; Heuckmann, J. M.; Koker, M.; Heynck, S.; Stückrath, I.; Weiss, J.; Fischer, F.; Michel, K.; Goel, A.; Regales, L.; Politi, K. A.; Perera, S.; Getlik, M.; Heukamp, L. C.; Ansén, S.; Zander, T.; Beroukhim, R.; Kashkar, H.; Shokat, K. M.; Sellers, W. R.; Rauh, D.; Orr, C.; Hoeflich, K. P.; Friedman, L.; Wong, K. K.; Pao, W.; Thomas, R. K. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. USA 2009, 106 (43), 18351-18356.
69. Hoeflich, K. P.; O'Brien, C.; Boyd, Z.; Cavet, G.; Guerrero, S.; Jung, K.; Januario, T.; Savage, H.; Punnoose, E.; Truong, T.; Zhou, W.; Berry, L.; Murray, L.; Amler, L.; Belvin, M.; Friedman, L. S.; Lackner, M. R. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009, 15 (14), 4649-4664.
70. Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita, M.; Melendez, Cuero. M.; Stutvoet, S.; Birle, D.; Anak, O.; Hackl, W.; Baselga, J. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 2012, 23 (9), 2399-2408.
71. Pal, S. K.; Williams, S.; Josephson, D. Y.; Carmichael, C.; Vogelzang, N. J.; Quinn, D. I. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol. Cancer Ther. 2012, 11 (3), 526-537.
72. Hosono, Y.; Osada, S.; Nawa, M.; Takahashi, T.; Yamaguchi, K.; Kawaguchi, Y.; Yoshida, K. Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer. Anticancer Res. 2010, 30 (7), 2625-2630.
73. Shi, Y.; Gera, J.; Hu, L.; Hsu, J. H.; Bookstein, R.; Li, W.; Lichtenstein, A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002, 62 (17), 5027-5034.
74. Noh, W. C.; Mondesire, W. H.; Peng, J.; Jian, W.; Zhang, H.; Dong, J.; Mills, G. B.; Hung, M. C.; Meric-Bernstam, F. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004, 10(3), 1013-1023.
75. O'Donnell, A.; Faivre, S.; Burris, H. A. 3rd.; Rea, D.; Papadimitrakopoulou, V.; Shand, N.; Lane, H. A.; Hazell, K.; Zoellner, U.; Kovarik, J. M.; Brock, C.; Jones, S.; Raymond, E.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26 (10), 1588-1595.
76. Ellard, S. L.; Clemons, M.; Gelmon, K. A.; Norris, B.; Kennecke, H.; Chia, S.; Pritchard, K.; Eisen, A.; Vandenberg, T.; Taylor, M.; Sauerbrei, E.; Mishaeli, M.; Huntsman, D.; Walsh, W.; Olivo, M.; McIntosh, L.; Seymour, L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J. Clin. Oncol. 2009, 27 (27), 4536-4541.
77. Guba, M.; von, Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8 (2), 128-135.
78. Baselga, J.; Campone, M.; Piccart, M.; Burris, H. A. 3rd.; Rugo, H. S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K. I.; Lebrun, F.; Beck, J. T.; Ito, Y.; Yardley, D.; Deleu, I.; Perez, A.; Bachelot, T.; Vittori, L.; Xu, Z.; Mukhopadhyay, P.; Lebwohl, D; Hortobagyi, G. N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366 (6), 520-529.
79. Bachelot, T.; Bourgier, C.; Cropet, C.; Ray-Coquard, I.; Ferrero, J. M.; Freyer, G.; Abadie-Lacourtoisie, S.; Eymard, J. C.; Debled, M.; Spaëth, D.; Legouffe, E.; Allouache, D; El Kouri, C.; Pujade-Lauraine, E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 2012, 30 (22), 2718-2724.
80. Moulder, S.; Gladish, G.; Ensor, J.; Gonzalez-Angulo, A. M; Cristofanilli, M.; Murray, J. L.; Booser, D.; Giordano, S. H.; Brewster, A.; Moore, J.; Rivera, E.; Hortobagyi, G. N.; Tran, H. T. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 2012, 118 (9), 2378-2384.
81. Sabine, V. S.; Sims, A. H.; Macaskill, E. J.; Renshaw, L.; Thomas, J. S.; Dixon, J. M.; Bartlett, J. M. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res. Treat. 2010, 122 (2), 419-428.
82. Baselga, J.; Semiglazov, V.; van Dam, P.; Manikhas, A.; Bellet, M.; Mayordomo, J.; Campone, M.; Kubista, E.; Greil, R.; Bianchi, G.; Steinseifer, J.; Molloy, B.; Tokaji, E.; Gardner, H.; Phillips, P.; Stumm, M.; Lane, H. A.; Dixon, J. M.; Jonat, W.; Rugo, H. S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin. Oncol. 2009, 27 (16), 2630-2637.
83. Baselga, J.; Campone, M.; Piccart, M.; Burris, H. A. 3rd.; Rugo, H. S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K. I.; Lebrun, F.; Beck, J. T.; Ito, Y.; Yardley, D.; Deleu, I.; Perez, A.; Bachelot, T.; Vittori, L.; Xu, Z.; Mukhopadhyay, P.; Lebwohl, D.; Hortobagyi, G. N. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366 (6), 520-529.
84. Jerusalem, G.; Fasolo, A.; Dieras, V.; Cardoso, F.; Bergh, J.; Vittori, L.; Zhang, Y.; Massacesi, C.; Sahmoud, T.; Gianni, L. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 2011, 125 (2), 447-455.
85. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R. J.; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (22), 2271-2281.
86. Miller, T. W.; Rexer, B. N.; Garrett, J. T.; Arteaga, C. L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011, 13 (6), 224.
87. Chan, S.; Scheulen, M. E.; Johnston, S.; Mross, K.; Cardoso, F.; Dittrich, C.; Eiermann, W.; Hess, D.; Morant, R.; Semiglazov, V.; Borner, M.; Salzberg, M.; Ostapenko, V.; Illiger, H. J.; Behringer, D.; Bardy-Bouxin, N.; Boni, J.; Kong, S.; Cincotta, M.; Moore, L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005, 23 (23), 5314-5322.
88. Bonilha, H. S.; Dawson, A. E. Creating a mastery experience during the voice evaluation. Voice 2012, 26 (5), 665.
89. Leary, A.; Dowsett, M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br. J. Cancer 2006, 95 (6), 661-666.
90. Fleming, G.F.; Ma, C. X.; Huo, D.; Sattar, H.; Tretiakova, M.; Lin, L.; Hahn, O. M.; Olopade, F. O.; Nanda, R.; Hoffman, P. C.; Naughton, M. J.; Pluard, T.; Conzen, S. D.; Ellis, M. J. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2012,136 (2), 355-363.
91. Khokhar, N. Z.; Altman, J. K.; Platanias, L. C. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr. Opin. Oncol. 2011, 23 (6), 578-586.
92. Sessa, C.; Tosi, D.; Viganò, L.; Albanell, J.; Hess, D.; Maur, M.; Cresta, S.; Locatelli, A.; Angst, R.; Rojo, F.; Coceani, N.; Rivera, V. M.; Berk, L.; Haluska, F.; Gianni, L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 2010, 21 (6), 1315-1322.
93. Chawla, S. P.; Staddon, A. P.; Baker, L. H.; Schuetze, S. M.; Tolcher A. W.; D'Amato, G. Z.; Blay, J. Y.; Mita, M. M.; Sankhala, K. K.; Berk, L.; Rivera, V. M.; Clackson, T.; Loewy, J. W.; Haluska, F. G.; Demetri, G. D. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J. Clin. Oncol. 2012, 30 (1), 78-84.
94. Gayle, S. S.; Arnold, S. L.; O'Regan, R. M.; Nahta, R. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anticancer Agents Med. Chem. 2012, 12 (2),151-162.
95. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J. E.; Zhang, W. G.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S. K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Abraham, R. T.; Zask, A.; Gibbons, J. J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70 (2), 621-631.